Renal Disease

Background: Dose-intensive intravenous melphalan with autol-ogous blood stem-cell transplantation induces remission of the plasma cell dyscrasia in a substantial proportion of patients with AL amyloidosis. The impact of this treatment on associated renal disease is not known. Objective: To determine the effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis–associated renal disease. Design: Prospective cohort study. Setting: Academic medical center. Patients: 65 patients with AL amyloidosis and urinary protein excretion greater than 1 g/24 h who received dose-intensive in-travenous melphalan and autologous blood stem-cell transplanta